898 related articles for article (PubMed ID: 20186853)
1. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.
Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA
Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
[TBL] [Abstract][Full Text] [Related]
4. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
6. Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease.
Hinrichs AL; Mintun MA; Head D; Fagan AM; Holtzman DM; Morris JC; Goate AM
Biol Psychiatry; 2010 Mar; 67(6):581-3. PubMed ID: 19892322
[TBL] [Abstract][Full Text] [Related]
7. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults.
Liang KY; Mintun MA; Fagan AM; Goate AM; Bugg JM; Holtzman DM; Morris JC; Head D
Ann Neurol; 2010 Sep; 68(3):311-8. PubMed ID: 20818789
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
[TBL] [Abstract][Full Text] [Related]
9. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
[TBL] [Abstract][Full Text] [Related]
10. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
[TBL] [Abstract][Full Text] [Related]
11. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
12. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
14. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
[TBL] [Abstract][Full Text] [Related]
15. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.
Glodzik-Sobanska L; Pirraglia E; Brys M; de Santi S; Mosconi L; Rich KE; Switalski R; Saint Louis L; Sadowski MJ; Martiniuk F; Mehta P; Pratico D; Zinkowski RP; Blennow K; de Leon MJ
Neurobiol Aging; 2009 May; 30(5):672-81. PubMed ID: 17920160
[TBL] [Abstract][Full Text] [Related]
16. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.
Luo J; Agboola F; Grant E; Masters CL; Albert MS; Johnson SC; McDade EM; Vöglein J; Fagan AM; Benzinger T; Massoumzadeh P; Hassenstab J; Bateman RJ; Morris JC; Perrin RJ; Chhatwal J; Jucker M; Ghetti B; Cruchaga C; Graff-Radford NR; Schofield PR; Mori H; Xiong C
Neurology; 2020 Dec; 95(23):e3104-e3116. PubMed ID: 32873693
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
18. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.
Fagan AM; Head D; Shah AR; Marcus D; Mintun M; Morris JC; Holtzman DM
Ann Neurol; 2009 Feb; 65(2):176-83. PubMed ID: 19260027
[TBL] [Abstract][Full Text] [Related]
19. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
